Investor Law Firms Rally uniQure Case as April 13 Lead-Plaintiff Deadline Nears

Overview

• Class actions on behalf of purchasers of uniQure shares from September 24 to October 31, 2025 are underway, with motions for lead plaintiff due by April 13, 2026.
• Complaints assert uniQure misrepresented the FDA’s stance on its AMT-130 Pivotal Study design, including use of ENROLL-HD data, and minimized the likelihood of a delayed BLA requiring additional studies.
• Rosen Law Firm and The Schall Law Firm detail alleged violations of Sections 10(b) and 20(a) of the Exchange Act and SEC Rule 10b-5.
• Berger Montague highlights market volatility, citing a nearly 250% share surge on September 24, 2025 after topline results and a drop of nearly 50% on November 3, 2025 after the FDA-related disclosure.
• No class has been certified at this stage, and multiple firms are soliciting investors to join the case or seek appointment to lead the litigation.